The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
As development costs climb and timelines tighten, the traditional outsourcing model is showing its age. Fragmented handoffs between CDMOs, CROs, and clinical supply vendors often create delays, inefficiencies, and missed opportunities.
A new study by the Tufts Center for the Study of Drug Development offers fresh insight by quantifying the financial and operational impact of a fully integrated development model.
The result? Up to 113x ROI and $62.9M in projected value for Phase III oncology programs alone.
Discover how aligning manufacturing, clinical, and supply services can reduce complexity, streamline execution, and unlock significant ROI.
Read the whitepaper to explore the full findings.
